难治与复发急性白血病p170和p26与多药耐药关系的分析  

The correlation between p170,p26 and multidrug resistance in refractory/relapse acute leukemia

作　　者：高秀华[1] 张晓辉[1] 乔振华 鹿育晋 

机构地区：[1]山西医科大学第二附属医院

出　　处：《中华血液学杂志》1998年第2期67-69,共3页Chinese Journal of Hematology

摘　　要：目的：探讨ｐ１７０和ｐ２６两种膜蛋白在临床耐药中的作用及相互关系。方法：用流式细胞仪技术检测了３９例急性白血病患者骨髓细胞的ｐ１７０和ｐ２６表达率。结果：两者在初治敏感组分别为１５．８９％±４．４１％和１７．３２％±１０．２０％，在难治复发组分别为３１．０２％±１４．３３％和３３．７８％±１５．９７％，两组差别均有显著性（Ｐ均＜０．０５），ｐ１７０与ｐ２６的相关性，ｒ＝－０．１５７８，Ｐ＞０．５。结论：两者均与临床多药耐药相关，但它们之间无明显相关性，揭示其耐药机制不同。Objective: To explore the role of two membrane proteins,p170 and p26,in clinical drug resistance and their correlation. Methods: The expression of p170 and p26 in bone marrow cells from 39 acute leukemia patients were detected by flow cytometry. Results: The expression ratios of p170 and p26 were 15.89%±4.41% and 17.32%±10.20%, respectively, in previously untreated group, and 31.02%±14.33% and 33.78%±15.97%, respectively, in refractory/relapse group. The difference between the two groups was significant, while there were no correlation between p170 and p26 ( r=-0.1578, P>05).Conclusion:Both p170 and p26 were related to clinical multidrug resistance,but the mechanisms were different.

关 键 词：白血病 细胞凋亡 多药抗药性 

分 类 号：R733.71[医药卫生—肿瘤]